Cargando…

Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma

BACKGROUND: Ovarian carcinosarcoma (OCS) is an uncommon, biphasic and highly aggressive ovarian cancer type, which has received relatively little research attention. METHODS: We curated the largest pathologically confirmed OCS cohort to date, performing detailed histopathological characterisation, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hollis, Robert L., Croy, Ian, Churchman, Michael, Bartos, Clare, Rye, Tzyvia, Gourley, Charlie, Herrington, C. Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470739/ https://www.ncbi.nlm.nih.gov/pubmed/35715633 http://dx.doi.org/10.1038/s41416-022-01874-8

Ejemplares similares

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma
por: Hollis, Robert L., et al.
Publicado: (2023)

Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification
por: Hollis, Robert L., et al.
Publicado: (2021)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
por: Hollis, Robert L., et al.
Publicado: (2022)

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
por: Hollis, Robert L., et al.
Publicado: (2020)

Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
por: Hollis, Robert L., et al.
Publicado: (2021)

Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma
por: Hollis, Robert L., et al.
Publicado: (2019)

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
por: Hollis, Robert L., et al.
Publicado: (2019)

Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse
por: Hollis, Robert L., et al.
Publicado: (2019)

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
por: Kang, Eun‐Young, et al.
Publicado: (2022)

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment
por: Xintaropoulou, Chrysi, et al.
Publicado: (2018)

Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer
por: Langdon, Simon P., et al.
Publicado: (2020)

Genetic and molecular changes in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2016)

Erratum to Genetic and molecular changes in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

A rare and distinct bilateral ovarian tumor: Carcinosarcoma
por: Limaiem, Faten, et al.
Publicado: (2021)

A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis
por: Communal, Laudine, et al.
Publicado: (2021)

Extirpation of a Tubo-Ovarian Cys
por: Archibald, R. A.
Publicado: (1893)

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma
por: Chan, Angela MY, et al.
Publicado: (2020)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Ovarian Carcinosarcoma and Response to Immunotherapy
por: Daniyal, Muhammad, et al.
Publicado: (2023)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Tubo-ovarian abscess in a virgin girl
por: Ashrafganjooei, Tahere, et al.
Publicado: (2011)

Case of Tubo-Ovarian Pregnancy, with Uterine Pregnancy
por: Mondy, S. L. Craigie
Publicado: (1903)

An Unusual Case of Tubo-Ovarian Inguinal Hernia
por: Orr, J. Leslie
Publicado: (1929)

Hydronephrosis Due to Bilateral Tubo-ovarian Abscess
por: Fite, Emily, et al.
Publicado: (2020)

Mesenteric ectopic pregnancy with tubo-ovarian abscess
por: Son, Sam Y., et al.
Publicado: (2021)

Low-grade serous ovarian cancer: expert consensus report on the state of the science
por: Grisham, Rachel N, et al.
Publicado: (2023)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma
por: Gornjec, Andreja, et al.
Publicado: (2019)

The impact of an educational and information systems initiative on somatic BRCA testing rates in patients with high grade serous tubo-ovarian cancer in Western Australia
por: Fantoni, Andrew, et al.
Publicado: (2023)

Etiology of Persistent Tubo-Ovarian Abscess in Nairobi, Kenya
por: Cohen, Craig R., et al.
Publicado: (2003)

Pneumoperitoneum caused by tubo-ovarian abscess in an elderly patient
por: Aguilera, Fabiola, et al.
Publicado: (2018)

Perforated Appendicitis Masquerading as Bilateral Tubo-Ovarian Abscess
por: Iqbal, Humzah
Publicado: (2022)

Current and Emerging Strategies for Tubo-Ovarian Cancer Diagnostics
por: Brincat, Mark R., et al.
Publicado: (2023)

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
por: Gershenson, David M, et al.
Publicado: (2022)

External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
por: Lee, Jung-Yun, et al.
Publicado: (2017)

Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
por: Saner, Flurina A. M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0f1jpql17natul56roscr1otsp